Mnemosyne Pharmaceuticals Inc.

Mnemosyne Pharmaceuticals Inc.

 

Mnemosyne is developing novel therapeutics that modify the activity of NMDA receptors to treat cognitive dysfunction in central nervous system (CNS) disorders. We are currently focused on modulating the activity of the NR2B subtype with our lead program targeting depression.

Mnemosyne was founded in 2010 with seed funding from Slater Technology Fund and angel investors. Additional investors who have funded the company include Clal Biotechnology Industries and Atlas Venture.